ATE72838T1 - Neue prokoagulierungsproteine. - Google Patents

Neue prokoagulierungsproteine.

Info

Publication number
ATE72838T1
ATE72838T1 AT86902972T AT86902972T ATE72838T1 AT E72838 T1 ATE72838 T1 AT E72838T1 AT 86902972 T AT86902972 T AT 86902972T AT 86902972 T AT86902972 T AT 86902972T AT E72838 T1 ATE72838 T1 AT E72838T1
Authority
AT
Austria
Prior art keywords
pct
region
proteins
polypeptide sequence
amino
Prior art date
Application number
AT86902972T
Other languages
English (en)
Inventor
John J Toole Jr
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24914180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE72838(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst filed Critical Genetics Inst
Application granted granted Critical
Publication of ATE72838T1 publication Critical patent/ATE72838T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/30—Signal or leader sequence
AT86902972T 1985-04-12 1986-04-11 Neue prokoagulierungsproteine. ATE72838T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72535085A 1985-04-12 1985-04-12
EP86902972A EP0218712B1 (de) 1985-04-12 1986-04-11 Neue prokoagulierungsproteine
PCT/US1986/000774 WO1986006101A1 (en) 1985-04-12 1986-04-11 Novel procoagulant proteins

Publications (1)

Publication Number Publication Date
ATE72838T1 true ATE72838T1 (de) 1992-03-15

Family

ID=24914180

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86902972T ATE72838T1 (de) 1985-04-12 1986-04-11 Neue prokoagulierungsproteine.

Country Status (12)

Country Link
US (1) US4868112A (de)
EP (1) EP0218712B1 (de)
JP (1) JPH0788399B2 (de)
AT (1) ATE72838T1 (de)
AU (2) AU5772886A (de)
CA (1) CA1341174C (de)
DE (1) DE3683980D1 (de)
DK (1) DK166457B1 (de)
ES (1) ES8801674A1 (de)
LU (1) LU90458I2 (de)
MX (1) MX9203440A (de)
WO (1) WO1986006101A1 (de)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
FI98829C (fi) * 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
IL84168A0 (en) * 1986-10-15 1988-03-31 Rorer Int Overseas Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
AU627150B2 (en) * 1987-06-12 1992-08-20 Immuno Ag Novel proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5171844A (en) * 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0294910B1 (de) * 1987-06-12 1996-09-11 Immuno Ag Proteine mit Faktor-VIII-Aktivität, Verfahren zu deren Herstellung unter Verwendung von genetisch modifizierten Zellen und diese enthaltende pharmazeutische Zusammensetzungen
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
JPH0387173A (ja) * 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
ATE163194T1 (de) * 1989-11-17 1998-02-15 Novo Nordisk As Proteinkomplexe mit faktor viii:c-aktivität und deren herstellung
US20050209121A1 (en) * 1990-12-05 2005-09-22 Novozymes A/S Proteins with changed epitopes and methods for the production thereof
US20060122376A1 (en) * 1991-02-07 2006-06-08 Chiron Corporation Protein complexes having factor VIII:C activity and production thereof
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
AU4535893A (en) * 1992-06-15 1994-01-04 Regents Of The University Of California, The Screening assay for the identification of immunosuppressive drugs
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
WO1994029471A1 (en) * 1993-06-10 1994-12-22 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
WO1995003332A1 (en) * 1993-07-23 1995-02-02 Baxter International Inc. Activated human factor viii and method of preparation
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
US5874562A (en) * 1995-06-07 1999-02-23 Progenitor, Inc. Nucleic acid encoding developmentally-regulated endothelial cell locus-1
US7041801B1 (en) 1995-06-07 2006-05-09 Vanderbilt University Antibodies binding to polypeptides encoded by developmentally-regulated endothelial cell locus-1
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
US8183344B2 (en) * 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US20040092442A1 (en) * 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
PT1754718E (pt) * 1996-04-24 2011-07-13 Univ Michigan Factor viii resistente à inactivação
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
AU735763B2 (en) * 1997-12-05 2001-07-12 Immune Response Corporation, The Novel vectors and genes exhibiting increased expression
US7820796B2 (en) * 1998-03-12 2010-10-26 Genetics Institute, Llc. Methods for producing Factor VIII proteins
JP4405668B2 (ja) 1998-03-12 2010-01-27 ジェネティクス インスティテュート，エルエルシー 因子ｖｉｉｉ蛋白を製造するための改良された方法
MXPA01002898A (es) 1998-09-21 2002-06-04 Genetics Inst Metodos de modulacion descendente de la respuesta inmune a proteinas terapeuticas.
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US7112438B2 (en) * 1999-01-04 2006-09-26 Dyax Corp. Binding molecules for human factor VIII and factor VIII-like proteins
CN100553678C (zh) 1999-02-22 2009-10-28 巴克斯特国际有限公司 新的无白蛋白的因子ⅷ制剂
US6517830B1 (en) * 1999-08-05 2003-02-11 Emory University Compositions and methods for the expression of factor VIII polypeptides and uses therefor
WO2002060951A2 (en) * 2001-01-12 2002-08-08 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
US7205278B2 (en) * 2001-06-14 2007-04-17 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
CN1630666A (zh) * 2001-11-30 2005-06-22 埃默里大学 因子ⅷc2结构域变体
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
SI1596887T1 (sl) 2003-02-26 2022-05-31 Nektar Therapeutics Konjugati polimer-del faktorja VIII
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US20050123997A1 (en) * 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
DK1750733T3 (da) 2004-05-03 2014-01-20 Univ Emory FREMGANGSMÅDE TIL INDGIVELSE AF SVINE-B-DOMÆNELØS fVIII
US20060080848A1 (en) * 2004-10-19 2006-04-20 Lace Charles R Wheel blade sight
EP1707634A1 (de) 2005-03-29 2006-10-04 Octapharma AG Verfahren zur Isolierung von rekombinant hergestellten Proteinen
EP1739179A1 (de) 2005-06-30 2007-01-03 Octapharma AG Serumfreie stabile Transfektion und Produktion von rekombinanten humanen Proteinen in humanen Zelllinien
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US20080070251A1 (en) 2006-06-30 2008-03-20 Kaufman Randal J Method of Producing Factor VIII Proteins by Recombinant Methods
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
WO2009082648A1 (en) 2007-12-21 2009-07-02 Inspiration Biopharmaceuticals, Inc. Stabilized factor ix formulations containing trehalose
ES2644089T3 (es) 2007-12-27 2017-11-27 Baxalta GmbH Procedimientos de cultivo celular
KR100981092B1 (ko) * 2008-02-29 2010-09-08 고려대학교 산학협력단 제8 혈액응고 인자와 폰 빌리 블란트 인자 변이체의 재조합발현 벡터 시스템
ES2441941T3 (es) 2008-10-15 2014-02-07 Baxter Healthcare Sa Pegilación de factores de coagulación sanguínea recombinantes en presencia de anticuerpos enlazados
CN116925238A (zh) 2009-02-03 2023-10-24 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
JP5936112B2 (ja) 2009-02-11 2016-06-15 アルブミディクス アクティーゼルスカブ アルブミン変異体及び複合体
US8691211B2 (en) * 2009-03-10 2014-04-08 Puget Sound Blood Center Suppression of immune response to factor VIII in hemophilia A patients
CN102741422B (zh) 2009-08-24 2016-06-08 阿穆尼克斯运营公司 凝血因子ⅶ组合物及其制备和使用方法
CN105567699A (zh) 2009-10-30 2016-05-11 诺维信生物制药丹麦公司 白蛋白变体
CN102791285A (zh) 2009-12-06 2012-11-21 比奥根艾迪克依蒙菲利亚公司 因子VIII-Fc嵌合多肽和杂交多肽及其使用方法
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
WO2012006623A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systems for factor viii processing and methods thereof
MX2013000301A (es) 2010-07-09 2013-05-09 Biogen Idec Hemophilia Inc Factores quimericos de coagulacion.
JP5922141B2 (ja) 2010-11-05 2016-05-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 増加した比活性を有する抗血友病第ｖｉｉｉ因子の新規変異体
BRPI1105317A2 (pt) 2011-01-24 2013-04-30 Fundacco Hemoct De Ribeirco Preto produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1
WO2012170969A2 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
EP2729161B1 (de) 2011-07-08 2018-12-19 Bioverativ Therapeutics Inc. Chimäre und hybride faktor-viii-polypeptide und verfahren zu ihrer anwendung
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
JP2014531910A (ja) 2011-10-18 2014-12-04 シーエスエル、リミテッド 再構成後の精製第ｖｉｉｉ因子の安定性を改善するための方法
KR20140083036A (ko) 2011-10-18 2014-07-03 체에스엘 베링 게엠베하 인자 ｖｉｉｉ의 생체이용률을 향상시키기 위한 황산화 글리코사미노글리칸의 용도
EP2768521B1 (de) 2011-10-18 2016-07-13 CSL Behring GmbH Kombinierte verwendung eines sulfatierten glycosaminglycans und einer hyaluronidase zur verbesserung der bioverfügbarkeit des blutgerinnungsfaktors viii
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
EP3453402B1 (de) 2012-01-12 2021-07-21 Bioverativ Therapeutics Inc. Reduzierung der immunogenität gegen den faktor viii bei patienten in einer faktor-viii-therapie
BR112014017165B1 (pt) 2012-01-12 2023-05-02 Bioverativ Therapeutics Inc Proteína quimérica compreendendo uma proteína de fator viii, composição farmacêutica, e seus usos
JP6383666B2 (ja) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド 組換え第ｖｉｉｉ因子タンパク質
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
BR112014018679A2 (pt) 2012-03-16 2017-07-04 Novozymes Biopharma Dk As variantes de albumina
AU2013270683A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Chimeric clotting factors
JP2015521589A (ja) 2012-06-08 2015-07-30 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． プロコアグラント化合物
EP2870250B2 (de) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Einkettige faktor-viii-polypeptide exprimierende zelllinie und verwendungen davon
SG10201913893XA (en) 2012-07-11 2020-03-30 Bioverativ Therapeutics Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
EP2877202A4 (de) 2012-07-25 2016-06-01 Biogen Ma Inc Blutfaktorüberwachungstest und verwendungen davon
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
US20150266944A1 (en) 2012-10-30 2015-09-24 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
EP3889173B1 (de) 2013-02-15 2023-07-05 Bioverativ Therapeutics Inc. Optimiertes faktor-viii-gen
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
PT3666283T (pt) 2013-03-15 2022-09-13 Bioverativ Therapeutics Inc Formulações de polipéptido de fator viii
EP3043813B1 (de) 2013-08-08 2021-01-13 Bioverativ Therapeutics Inc. Reinigung von chimären fviii-molekülen
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EP3760639A1 (de) 2013-09-08 2021-01-06 Kodiak Sciences Inc. Zwitterionische polymerkonjugate
EP3065769A4 (de) 2013-11-08 2017-05-31 Biogen MA Inc. Prokoagulatorische fusionsverbindung
EP4332839A2 (de) 2013-12-06 2024-03-06 Bioverativ Therapeutics Inc. Pharmakokinetische werkzeuge für populationen und verwendungen davon
RS63583B1 (sr) 2014-01-10 2022-10-31 Bioverativ Therapeutics Inc Himerni proteini faktora viii i njihova upotreba
EP3102589A1 (de) 2014-02-04 2016-12-14 Biogen MA Inc. Verwendung von kationenaustauscherchromatographie im durchflussmodus zur anreicherung von posttranslationalen modifikationen
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
CN104630131B (zh) * 2015-01-15 2017-08-15 上海交通大学 一种稳定表达人凝血八因子的cho细胞株及其应用
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
EP3167877A1 (de) 2015-11-12 2017-05-17 Bayer Pharma Aktiengesellschaft Verfahren zur herstellung von gefriergetrockneten pellets mit faktor viii
KR102404550B1 (ko) 2015-11-13 2022-05-31 다케다 야쿠힌 고교 가부시키가이샤 A형 혈우병의 유전자 요법을 위한 증가된 발현을 갖는 재조합 fviii 변이체를 인코딩하는 바이러스 벡터
EA202190827A1 (ru) 2015-11-13 2021-11-30 Баксалта Инкорпорейтед Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
DK3411478T3 (da) 2016-02-01 2022-09-12 Bioverativ Therapeutics Inc Optimerede faktor viii-gener
CN109790529A (zh) 2016-06-24 2019-05-21 财团法人牧岩生命科学研究所 包含FVIII和vWF因子的嵌合蛋白及其用途
BR112019011198A2 (pt) 2016-12-02 2019-12-17 Bioverativ Therapeutics Inc métodos de indução de tolerância imune a fatores de coagulação
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
CN111247251A (zh) 2017-08-09 2020-06-05 比奥维拉迪维治疗股份有限公司 核酸分子及其用途
KR20200057051A (ko) 2017-09-27 2020-05-25 시질론 테라퓨틱스, 인크. 활성 세포를 포함하는 방법, 조성물 및 이식 가능한 요소
BR112020015228A2 (pt) 2018-02-01 2020-12-29 Bioverativ Therapeutics Inc. Uso de vetores lentivirais que expressam fator viii
CA3096038A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Implantable particles and related methods
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
MA52630A (fr) 2018-05-18 2021-05-26 Bioverativ Therapeutics Inc Procédés de traitement de l'hémophilie a
MX2021000582A (es) 2018-07-16 2021-04-12 Baxalta Inc Terapia genica de hemofilia a mediante el uso de vectores virales que codifican variantes del factor viii (fviii) recombinantes con mayor expresion.
EP3833766A1 (de) 2018-08-09 2021-06-16 Bioverativ Therapeutics Inc. Nukleinsäuremoleküle und verwendungen davon zur nichtviralen gentherapie
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
TW202039546A (zh) 2019-01-16 2020-11-01 美商巴克斯歐塔公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
WO2020257462A1 (en) 2019-06-19 2020-12-24 Bioverativ Therapeutics Inc. Recombinant factor viii-fc for treating hemophilia and low bone mineral density
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021119357A2 (en) 2019-12-12 2021-06-17 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
WO2022264040A1 (en) 2021-06-14 2022-12-22 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
CA3229323A1 (en) 2021-08-23 2023-03-02 Ajay MAGHODIA Optimized factor viii genes
CA3232988A1 (en) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3588242T2 (de) * 1984-01-12 2004-03-11 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Für Faktor-VIIIc kodierende DNA-Sequenzen und verwandte DNA-Konstruktionen
ZA852099B (en) * 1984-03-26 1985-12-24 Meloy Lab Recombinant factor viii-c.
IL74909A (en) * 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein

Also Published As

Publication number Publication date
WO1986006101A1 (en) 1986-10-23
AU5753490A (en) 1991-02-07
JPS62502941A (ja) 1987-11-26
LU90458I2 (fr) 2001-04-13
EP0218712A1 (de) 1987-04-22
DK166457B1 (da) 1993-05-24
EP0218712B1 (de) 1992-02-26
AU5772886A (en) 1986-11-05
ES8801674A1 (es) 1988-02-16
DK601786D0 (da) 1986-12-12
CA1341174C (en) 2001-01-30
JPH0788399B2 (ja) 1995-09-27
ES553935A0 (es) 1988-02-16
DE3683980D1 (de) 1992-04-02
AU629649B2 (en) 1992-10-08
DK601786A (da) 1986-12-12
EP0218712A4 (de) 1987-10-27
US4868112A (en) 1989-09-19
MX9203440A (es) 1992-07-01

Similar Documents

Publication Publication Date Title
ATE72838T1 (de) Neue prokoagulierungsproteine.
ISEMURA et al. Isolation and amino acid sequence of SAP-1, an acidic protein of human whole saliva, and sequence homology with human γ-trace
KR880701105A (ko) 신규 응혈촉진 단백질
BR9506733A (pt) Proteina de fusão de hematopoiese il-3 multivarian
NL300106I2 (nl) N-terminaal chemisch gemodificeerde eiwitpreparaten en werkwijzen.
DE69840195D1 (de) Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1
DE59007517D1 (de) Neue proteine mit tnf-hemmender wirkung und ihre herstellung.
IT1153265B (it) Polipeptidi contenenti la sequenza degli amminoacidi dell'interferone umano immune (interferone umano gamma), relativi veicoli di espressione, loro procedimento di preparazione, composizioni farmaceutiche contenenti tali polipeptidi
CA2025598A1 (en) Chimaeric hepadnavirus core antigen proteins
DE3486154D1 (de) Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung.
IL134982A0 (en) Antibodies which react with polypeptides of cd-44 surface proteins and diagnostic and pharmaceutical compositions prepared therewith
ES2007425A6 (es) Un metodo para la produccion de una proteina con actividad inhibidora del crecimiento de tumores.
DE69926627D1 (de) Insulinartigen wachstumsfaktor bindendes protein -3 variante
DE69233245D1 (de) Verfahren zur Herstellung von Peptiden
EP0310887A3 (en) Vasoconstrictor peptide
EP0330700A4 (de) Menschlicher Prourokinase ähnliches Polypeptid.
KR860000072A (ko) 임균 예방 백신의 제조방법
GB1294771A (en) Thyrocalcitonin derivative
DE3650035D1 (de) THF-Zusammensetzungen.
ES2033212A6 (es) Procedimiento para la obtencion de peptidos puramente glicosilados, parcialmente glicosilados o no glicosilados.
EP0723016A3 (de) Leukocyten-aktivierender Faktor